OPTN Stock Price, Optinose Inc Quote, Chart

Market Summary

USD1.030.00

Delayedas of 08 May 2024, 02:51 pm

0.00%

OPTN Stock Price

View Fullscreen

OPTN RSI Chart

OPTN Valuation

Market Cap

116.0M

Price/Earnings (Trailing)

-3.27

Price/Sales (Trailing)

1.63

Price/Free Cashflow

-5.56

OPTN Price/Sales (Trailing)

OPTN Profitability

Return on Equity

40.97%

Return on Assets

-32.94%

Free Cashflow Yield

-17.98%

OPTN Fundamentals

OPTN Revenue

Revenue (TTM)

71.0M

Rev. Growth (Yr)

-4.75%

Rev. Growth (Qtr)

0.21%

OPTN Earnings

Earnings (TTM)

-35.5M

Earnings Growth (Yr)

34.2%

Earnings Growth (Qtr)

-7.25%

Breaking Down OPTN Revenue

52 Week Range

0.902.03

(Low)(High)

Last 7 days

24.4%

Last 30 days

-22.7%

Last 90 days

-19.0%

Trailing 12 Months

-46.0%

How does OPTN drawdown profile look like?

OPTN Financial Health

Current Ratio

0.6

OPTN Investor Care

Shares Dilution (1Y)

0.75%

Diluted EPS (TTM)

-0.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	73.4M	72.2M	72.0M	71.0M
2022	77.5M	79.7M	77.9M	76.3M
2021	54.0M	62.1M	68.5M	74.7M
2020	40.3M	35.5M	38.6M	49.1M
2019	10.7M	16.1M	29.2M	39.9M
2018	31.3M	23.2M	15.2M	7.1M
2017	0	0	0	39.4M
2016	0	0	0	47.5M
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Optinose Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	krick anthony j	sold	-4,408	1.88	-2,345	chief accounting officer
Mar 18, 2024	marino michael f iii	sold	-28,310	1.88	-15,059	chief legal officer & corp sec
Mar 18, 2024	mahmoud ramy a	sold	-36,092	1.88	-19,198	chief executive officer
Mar 15, 2024	mahmoud ramy a	acquired	-	-	6,114	chief executive officer
Mar 15, 2024	marino michael f iii	acquired	-	-	3,816	chief legal officer & corp sec
Feb 28, 2024	mahmoud ramy a	acquired	-	-	795,975	chief executive officer
Feb 28, 2024	krick anthony j	acquired	-	-	112,500	chief accounting officer
Feb 28, 2024	marino michael f iii	acquired	-	-	280,000	chief legal officer & corp sec
Feb 28, 2024	spence paul jr.	acquired	-	-	252,675	chief commercial officer
Jan 31, 2024	mahmoud ramy a	sold	-69,266	1.31	-52,875	chief executive officer

Which funds bought or sold OPTN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	HighTower Advisors, LLC	unchanged	-	5,000	44,000	-%
May 06, 2024	SG Americas Securities, LLC	sold off	-100	-22,000	-	-%
May 03, 2024	Geneos Wealth Management Inc.	new	-	7,338	7,338	-%
May 03, 2024	EASTERLY INVESTMENT PARTNERS LLC	added	33.97	1,013,050	2,975,540	0.23%
May 03, 2024	GSA CAPITAL PARTNERS LLP	added	212	80,000	111,000	0.01%
May 03, 2024	VICTORY CAPITAL MANAGEMENT INC	reduced	-19.32	-1,464	15,387	-%
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	new	-	31.00	31.00	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	reduced	-3.53	21,920	260,629	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	11.00	11.00	-%

Are Funds Buying or Selling OPTN?

Are funds buying OPTN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OPTN

No. of Funds

Unveiling Optinose Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	5.14%	4,541,489	SC 13G/A
Feb 22, 2024	rosalind advisors, inc.	4.4%	4,885,580	SC 13G/A
Feb 14, 2024	rosalind advisors, inc.	5.2%	479,990	SC 13G/A
Feb 14, 2024	great point partners llc	9.99%	11,484,120	SC 13G/A
Feb 13, 2024	acorn bioventures, l.p.	4.4%	5,067,698	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	kruttschnitt theodore h iii	7.98%	9,105,789	SC 13G/A
Jan 30, 2024	avista capital partners ii gp, llc	0%	0	SC 13G/A
Jul 28, 2023	rosalind advisors, inc.	5.8%	6,435,000	SC 13G
Feb 14, 2023	mvm partners, llc	14.9%	16,710,526	SC 13D/A

Recent SEC filings of Optinose Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	8-K	Current Report
Apr 25, 2024	SC 13G/A	Major Ownership Report
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	8-K	Current Report
Mar 14, 2024	8-K	Current Report
Mar 08, 2024	8-K	Current Report

Peers (Alternatives to Optinose Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.6B	-2.43%	-8.39%	9.3	4.18	5.68%	202.39%
MRK	330.2B	61.4B	1.86%	10.13%	143.19	5.38	6.11%	-82.30%
AMGN	161.1B	29.5B	11.28%	28.04%	42.82	5.46	12.76%	-52.47%
PFE	156.8B	46.5B	4.16%	-28.19%	-112.94	3.37	42.59%	-114.62%
GILD	81.5B	27.1B	-5.96%	-16.75%	14.39	3.01	-0.60%	23.36%
TEVA	15.6B	15.8B	-2.04%	54.08%	-27.14	0.99	6.17%	76.47%
MID-CAP
ALKS	4.2B	1.7B	-5.86%	-20.45%	9.58	2.41	54.01%	364.56%
PRGO	4.1B	4.6B	-3.95%	-16.22%	-533.77	0.9	-0.06%	94.55%
BHC	2.7B	9.0B	-28.82%	23.71%	-5.97	0.3	10.01%	-27.45%
AMPH	2.1B	644.4M	2.42%	17.52%	14.96	3.19	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-23.46%	-28.42%	-4.38	2.07	24.65%	80.36%
TXMD	23.2M	1.3M	-9.05%	-48.20%	-2.26	17.8	-98.14%	-109.18%
ACRX	17.0M	-	-15.25%	35.14%	-0.92	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	31.03%	-94.02%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Optinose Inc News

Latest updates

Optinose Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q3	2019Q2	2019Q1
Revenue	0.2%	19,864,500	19,823,000	19,454,000	11,846,000	20,856,000	20,078,000	20,582,000	14,760,000	22,509,000	21,826,000	18,357,000	11,960,000	16,347,000	15,436,000	10,272,000	7,062,000	5,819,000	12,397,000	15,000,000	6,677,000	4,476,000
Costs and Expenses	4.0%	22,377,500	21,517,000	23,626,000	26,214,000	29,212,000	30,878,000	35,927,000	36,155,000	34,175,000	34,866,000	37,912,000	34,149,000	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	34,866,000	37,912,000	34,149,000	-	33,320,000	32,871,000	33,348,000	-	32,206,000	-	32,384,000	31,640,000
S&GA Expenses	5.3%	18,960,500	18,011,000	20,104,000	22,723,000	23,310,000	25,486,000	29,514,000	29,339,000	26,340,000	25,801,000	27,308,000	27,184,000	28,106,000	24,575,000	25,697,000	27,060,000	26,545,000	25,270,000	-	26,000,000	26,340,000
R&D Expenses	0.4%	1,286,000	1,281,000	951,000	1,785,000	2,921,000	3,267,000	4,270,000	4,802,000	5,260,000	6,654,000	8,179,000	5,225,000	6,448,000	6,524,000	5,474,000	4,932,000	5,379,000	5,547,000	-	5,295,000	4,562,000
EBITDA Margin	-	-	-	-	-	-	-	-0.82	-0.85	-0.88	-	-	-1.56	-1.74	-2.21	-2.40	-2.65	-2.87	-3.61	-5.98	-5.98	-9.05
Interest Expenses	3.1%	5,092,000	4,940,000	4,824,000	4,672,000	4,477,500	4,207,000	4,086,000	4,073,000	4,013,500	4,072,000	4,012,000	3,876,000	3,502,000	3,350,000	3,293,000	2,863,000	2,474,500	2,372,000	-	2,389,000	2,388,000
EBT Margin	-	-	-	-	-	-	-	-1.03	-1.06	-1.10	-	-	-1.85	-2.03	-2.51	-2.70	-2.96	-3.18	-4.01	-6.63	-6.63	-9.99
Net Income	-7.2%	-9,967,500	-9,294,000	2,626,000	-18,847,000	-15,149,000	-14,954,000	-19,397,000	-25,333,000	-15,624,000	-17,117,000	-23,502,000	-26,053,000	-23,863,000	-21,214,000	-25,852,000	-28,856,000	-24,995,000	-28,808,000	-	-27,376,000	-28,874,000
Net Income Margin	11.5%	-0.50	-0.56	-0.64	-0.93	-0.98	-0.97	-0.97	-1.05	-1.10	-1.32	-1.52	-1.80	-	-	-	-	-	-	-	-	-
Free Cashflow	248.6%	6,836,000	-4,601,000	-12,617,000	-10,478,000	-17,683,000	-17,508,000	-13,140,000	-19,383,000	-16,740,000	-9,729,000	-22,518,000	-28,115,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	6.2%	108	101	106	115	144	105	123	134	166	132	140	158	189	181	153	174	173	149	167	193	217
Current Assets	6.8%	105	99.00	104	112	140	101	118	128	160	125	133	150	181	172	149	170	168	144	161	187	213
Cash Equivalents	10.2%	74.00	67.00	71.00	84.00	94.00	61.00	78.00	91.00	111	84.00	94.00	116	144	143	125	149	147	126	144	171	201
Inventory	0.1%	8.00	8.00	8.00	8.00	9.00	10.00	11.00	11.00	12.00	13.00	13.00	13.00	9.00	9.00	6.00	6.00	3.00	4.00	4.00	6.00	7.00
Net PPE	-7.6%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00
Liabilities	8.6%	194	179	176	189	201	179	184	179	188	183	177	175	182	153	140	139	111	105	98.00	101	98.00
Current Liabilities	7.6%	177	164	164	166	179	178	55.00	50.00	59.00	54.00	47.00	45.00	52.00	43.00	35.00	34.00	36.00	30.00	24.00	27.00	26.00
Long Term Debt	-	-	-	-	-	-	-	127	127	126	127	126	126	125	105	105	105	75.00	74.00	73.00	73.00	73.00
LT Debt, Current	0.3%	130	130	129	129	129	128	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	126	-	-	-	125	-	-	-	75.00	-	-	-	73.00
Shareholder's Equity	-Infinity%	-86.61	-	-	-	-56.62	-	-	-	-21.77	-	-	-	7.00	28.00	13.00	35.00	62.00	45.00	68.00	92.00	119
Retained Earnings	-1.4%	-720	-710	-701	-703	-684	-669	-654	-635	-610	-594	-577	-553	-527	-503	-482	-456	-427	-402	-374	-346	-317
Additional Paid-In Capital	0.2%	634	633	631	630	628	596	594	591	588	543	540	537	535	532	495	492	490	448	443	439	437
Shares Outstanding	0.1%	112	112	112	112	111	83.00	83.00	82.00	82.00	53.00	53.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	119	-	-	-	202	-	-	-	95.00	-	-	-	176	-	-	-	174	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	256.1%	6,909	-4,425	-12,538	-10,478	-17,680	-17,498	-13,138	-19,335	-16,716	-9,701	-22,494	-28,024	-19,156	-15,532	-23,550	-27,968	-18,106	-15,127	-27,888	-29,694	-20,194
Share Based Compensation	-18.1%	979	1,195	1,501	1,523	1,486	1,947	3,447	1,997	1,976	2,684	2,733	2,610	2,492	2,625	2,772	2,460	2,308	2,435	2,695	2,422	2,218
Cashflow From Investing	58.5%	-73.00	-176	-79.00	-	-3.00	-10.00	-2.00	-48.00	-24.00	-28.00	81.00	-91.00	-86.00	-151	-239	-70.00	-72.00	-62.00	-255	-168	-240
Cashflow From Financing	-97.0%	4.00	135	-1.00	162	50,787	373	27.00	249	43,009	35.00	347	-71.00	20,308	33,552	572	29,378	39,831	-3,283	793	188	-83.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OPTN Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenues	$ 70,987	$ 76,276
Costs and expenses:
Cost of product sales	8,633	9,263
Research and development	5,303	15,260
Selling, general and administrative	79,799	107,649
Total costs and expenses	93,735	132,172
Loss from operations	(22,748)	(55,896)
Other (income) expense:
Unrealized (gain) loss on fair value of warrants	(4,290)	1,211
Other (income) expense	24	1,396
Interest income	(2,527)	(513)
Interest expense	19,528	16,843
Net loss	$ (35,483)	$ (74,833)
Net (loss) income per share of common stock, basic (in dollars per share)	$ (0.32)	$ (0.87)
Net (loss) income per share of common stock, diluted (in dollars per share)	$ (0.32)	$ (0.87)
Weighted average common shares outstanding, basic (in shares)	112,080,062	85,900,139
Weighted average common shares outstanding, diluted (in shares)	112,080,062	85,900,139
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Net product revenues	Net product revenues
Net product revenues
Total revenues	$ 70,987	$ 76,276

OPTN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 73,684	$ 94,244
Accounts receivable, net	19,926	33,932
Inventory	8,052	9,443
Prepaid expenses and other current assets	3,671	2,865
Total current assets	105,333	140,484
Property and equipment, net	815	795
Other assets	1,581	2,943
Total assets	107,729	144,222
Current liabilities:
Accounts payable	3,886	5,291
Accrued expenses and other current liabilities	42,411	44,864
Short term debt, net	130,227	128,575
Total current liabilities	176,524	178,730
Warrant liability	17,200	21,490
Other liabilities	611	626
Total liabilities	194,335	200,846
Stockholders' deficit:
Common stock, $0.001 par value; 350,000,000 and 200,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively ; 112,399,495 and 111,492,761 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	112	111
Additional paid-in capital	633,742	628,242
Accumulated deficit	(720,376)	(684,893)
Accumulated other comprehensive loss	(84)	(84)
Total stockholders' deficit	(86,606)	(56,624)
Total liabilities and stockholders' deficit	$ 107,729	$ 144,222

About Optinose Inc

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

CEO	Dr. Ramy A. Mahmoud M.D., M.P.H.
WEBSITE	optinose.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	141

Optinose Inc Frequently Asked Questions

What is the ticker symbol for Optinose Inc? What does OPTN stand for in stocks?

OPTN is the stock ticker symbol of Optinose Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Optinose Inc (OPTN)?

As of Tue May 07 2024, market cap of Optinose Inc is 116.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPTN stock?

You can check OPTN's fair value in chart for subscribers.

What is the fair value of OPTN stock?

You can check OPTN's fair value in chart for subscribers. The fair value of Optinose Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Optinose Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OPTN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Optinose Inc a good stock to buy?

The fair value guage provides a quick view whether OPTN is over valued or under valued. Whether Optinose Inc is cheap or expensive depends on the assumptions which impact Optinose Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPTN.

What is Optinose Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, OPTN's PE ratio (Price to Earnings) is -3.27 and Price to Sales (PS) ratio is 1.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPTN PE ratio will change depending on the future growth rate expectations of investors.